Expression data from fibroblast growth factor receptor 4 (FGFR4) knock down ovarian cancer cell lines

ABSTRACT: Advanced ovarian cancer is the most lethal gynecologic malignancy in the United States. Currently patients are treated by surgical cytoreductive surgery with the aim of reducing tumor burden to microscopic disease followed by adjuvant combined treatment with a platinum and taxane containing chemotherapy, which affords 80% of patients an initial complete response. However, Abdominal and pelvic recurrence rates are high and response to further chemotherapy is limited. Attempts at introducing biologic therapeutic agents to improve outcome in this disease are ongoing, while prognostic or predictive biomarkers that can stratify patients for treatment are still lacking. Using a 60-mer 22K oligonucleotide-based array comparative genome hybridization (CGH) platform combined with DNA isolated f

ORGANISM(S): Homo sapiens

SUBMITTER: Tsz-Lun Yeung 

PROVIDER: E-GEOD-34828 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress